Evaluation and Natural History of Children With Cancer and AIDS

Back to results

Primary Purpose

Status

Completed

Phase

Locations

United States

Study Type

Observational

Intervention

About this trial

This is an observational trial for Acquired Immunodeficiency Syndrome focused on measuring AIDS, Children, Human Immunodeficiency Virus

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Children with cancer (or a precancer syndrome) or HIV infection, between the age(s) of 3 months to 30 years, who are evaluated by the Pediatric Branch and are found to be not immediately eligible for an ongoing protocol but are likely to become a candidate for a future protocol. Children with cancer (or a precancer syndrome) or HIV infection, who present with disease manifestations of special interest to Pediatric Branch investigators, because they are likely to shed light on disease. Patients who, when evaluated by the Branch, are determined to likely never become eligible for a Pediatric Branch protocol are not eligible for this protocol. No patients younger than 3 months of age or older than 30 years of age are eligible for this protocol.

Sites / Locations

National Cancer Institute (NCI)

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

NCT ID

NCT00001424

First Posted

November 3, 1999

Last Updated

March 3, 2008

Sponsor

National Cancer Institute (NCI)

1. Study Identification

Unique Protocol Identification Number

NCT00001424

Brief Title

Evaluation and Natural History of Children With Cancer and AIDS

Official Title

Evaluation and Natural History of Children With Cancer and AIDS

Study Type

Observational

2. Study Status

Record Verification Date

October 1999

Overall Recruitment Status

Completed

Study Start Date

November 1994 (undefined)

Primary Completion Date

undefined (undefined)

Study Completion Date

August 2000 (undefined)

3. Sponsor/Collaborators

Name of the Sponsor

National Cancer Institute (NCI)

4. Oversight

5. Study Description

Brief Summary

Patients enrolled in this study will not receive investigational therapy. Any treatments rendered will be standard and based on appropriate medical care. Should a patient become eligible for an experimental therapy protocol, the normal process of enrollment and informed consent will be followed.

Detailed Description

This protocol will enable the Pediatric Branch to follow selected children with cancer or HIV infection who are not immediately eligible for protocol enrollment but who are likely, within the next year, to become candidates for protocol entry. It will also enable the Pediatric Branch to follow children who present with either clinical findings that constitute important educational experiences for the NCI trainees or who have unique or unusual medical problems that are likely to benefit from the research expertise of the NCI.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Acquired Immunodeficiency Syndrome, Cancer, HIV Infections, Leukemia, Lymphoma

Keywords

AIDS, Children, Human Immunodeficiency Virus

7. Study Design

Enrollment

110 (false)

10. Eligibility

Sex

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Children with cancer (or a precancer syndrome) or HIV infection, between the age(s) of 3 months to 30 years, who are evaluated by the Pediatric Branch and are found to be not immediately eligible for an ongoing protocol but are likely to become a candidate for a future protocol. Children with cancer (or a precancer syndrome) or HIV infection, who present with disease manifestations of special interest to Pediatric Branch investigators, because they are likely to shed light on disease. Patients who, when evaluated by the Branch, are determined to likely never become eligible for a Pediatric Branch protocol are not eligible for this protocol. No patients younger than 3 months of age or older than 30 years of age are eligible for this protocol.

Facility Information:

Facility Name

National Cancer Institute (NCI)

City

Bethesda

State/Province

Maryland

ZIP/Postal Code

20892

Country

United States

Acquired Immunodeficiency Syndrome, Cancer, HIV Infections

About this trial

Eligibility Criteria

Sites / Locations

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

1. Study Identification

2. Study Status

3. Sponsor/Collaborators

4. Oversight

5. Study Description

6. Conditions and Keywords

7. Study Design

10. Eligibility

12. IPD Sharing Statement

Learn more about this trial